Clonshaugh Business and Technology Park
Dublin D17 E400
Industry: Drug Manufacturers—General
Full Time Employees: 16,900
|Mr. Brenton L. Saunders||Chairman, Pres & CEO||4.48M||N/A||1970|
|Mr. Matthew M. Walsh||Exec. VP & CFO||9.84M||N/A||1967|
|Mr. A. Robert D. Bailey||Exec. VP, Chief Legal Officer & Corp. Sec.||2.35M||N/A||1963|
|Mr. William Meury||Exec. VP & Chief Commercial Officer||3.03M||4.06M||1968|
|Dr. C. David Nicholson||Exec. VP and Chief R&D Officer||2.59M||N/A||1955|
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has a collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and gene therapy research collaboration with The National Institute for Bioprocessing Research and Training. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Allergan plc’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 8; Compensation: 7.